Merck, Inc.

🇵🇭Philippines

Country: 🇵🇭Philippines

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

Phase 1

Recruiting

Conditions: Neoplasm Metastasis

Interventions: Biological: MK-6837
Biological: Pembrolizumab

First Posted Date: 2024-06-14

Last Posted Date: 2024-12-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT06460961

Locations: 🇨🇦
Princess Margaret Cancer Centre ( Site 2001), Toronto, Ontario, Canada
🇺🇸
Atlantic Health System Morristown Medical Center ( Site 4001), Morristown, New Jersey, United States
🇺🇸
Providence Portland Medical Center ( Site 4002), Portland, Oregon, United States

and more 3 locations

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Phase 3

Recruiting

Conditions: Cervical Cancer

Interventions: Biological: Sacituzumab Tirumotecan
Drug: Pemetrexed
Biological: Tisotumab Vedotin
Drug: Topotecan
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Irinotecan

First Posted Date: 2024-06-14

Last Posted Date: 2024-12-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 686

Registration Number: NCT06459180

Locations: 🇫🇷
Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 1506), Paris, France
🇬🇷
Aretaieio Hospital ( Site 1700), Athens, Attiki, Greece
🇬🇷
Mitera Hospital ( Site 1702), Athens, Attiki, Greece

and more 144 locations

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Phase 3

Recruiting

Conditions: Essential Thrombocythemia

Interventions: Drug: Bomedemstat
Drug: Hydroxyurea
Drug: Hydroxyurea placebo
Drug: Bomedemstat placebo

First Posted Date: 2024-06-13

Last Posted Date: 2024-12-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT06456346

Locations: 🇦🇷
Hospital Universitario Austral ( Site 0101), Pilar, Buenos Aires, Argentina
🇨🇱
FALP-UIDO ( Site 0148), Santiago, Region M. De Santiago, Chile
🇩🇪
VK&K Studien GbR ( Site 0370), Landshut, Bayern, Germany

and more 75 locations

A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn

Phase 3

Active, not recruiting

Conditions: Hypercholesterolemia

Interventions: Drug: Enlicitide Decanoate
Drug: Ezetimibe
Drug: Bempedoic Acid
Other: Placebo for Ezetimibe
Other: Placebo for Enlicitide Decanoate
Other: Placebo for Bempedoic Acid

First Posted Date: 2024-06-10

Last Posted Date: 2024-12-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT06450366

Locations: 🇺🇸
Clinical Trials Research ( Site 1509), Lincoln, California, United States
🇺🇸
Velocity Clinical Research Rockville ( Site 1503), Rockville, Maryland, United States
🇺🇸
Rainier Clinical Research Center ( Site 1502), Renton, Washington, United States

and more 32 locations

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Phase 1

Recruiting

Conditions: Gastroesophageal Adenocarcinoma
Esophageal Neoplasms
Gastroesophageal Junction
Esophageal Cancer

Interventions: Biological: Ramucirumab
Biological: MK-2870
Drug: Paclitaxel

First Posted Date: 2024-06-06

Last Posted Date: 2024-12-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 90

Registration Number: NCT06445972

Locations: 🇫🇷
Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi, Brest, Finistere, France
🇫🇷
Pitie Salpetriere University Hospital-Hepato-Gastro-Enterology ( Site 7102), Paris, France
🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 7200), Milan, Lombardia, Italy

and more 22 locations

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Phase 1

Recruiting

Conditions: Hepatic Impairment (HI)

Interventions: Drug: Nemtabrutinib

First Posted Date: 2024-06-04

Last Posted Date: 2024-10-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT06442436

Locations: 🇺🇸
Texas Liver Institute ( Site 0002), San Antonio, Texas, United States
🇺🇸
Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: IV Tulisokibart
Other: SC Placebo
Other: IV Placebo
Drug: SC Tulisokibart

First Posted Date: 2024-05-28

Last Posted Date: 2025-01-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT06430801

Locations: 🇷🇴
ASOCIATIA ONCOHELP ( Site 1805), Timisoara, Timis, Romania
🇷🇴
S.C. Centrul Medical Medicum SRL-Gastroenterology ( Site 1804), Bucuresti, Romania
🇸🇬
Changi General Hospital ( Site 6203), Singapore, South East, Singapore

and more 234 locations

Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-043)

Phase 3

Recruiting

Conditions: Systolic Dysfunction

Interventions: Drug: Vericiguat tablet
Drug: Vericiguat suspension

First Posted Date: 2024-05-24

Last Posted Date: 2024-12-17

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 342

Registration Number: NCT06428383

Locations: 🇮🇪
Children's Health Ireland (CHI) at Crumlin ( Site 1400), Dublin, Ireland
🇺🇸
Le Bonheur Children's Hospital ( Site 0007), Memphis, Tennessee, United States
🇨🇴
Clinica Somer-Unidad de Investigacion y Docencia ( Site 0607), Rionegro, Antioquia, Colombia

and more 2 locations

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Belzutifan
Drug: Everolimus
Drug: Fulvestrant
Drug: Exemestane

First Posted Date: 2024-05-24

Last Posted Date: 2024-12-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT06428396

Locations: 🇦🇷
Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0504), Caba, Buenos Aires, Argentina
🇦🇷
Instituto de Oncología de Rosario ( Site 0501), Rosario, Santa Fe, Argentina
🇨🇱
Pontificia Universidad Catolica de Chile ( Site 4108), Santiago, Region M. De Santiago, Chile

and more 11 locations

A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

Phase 1

Recruiting

Conditions: Colorectal Cancer
Biliary Tract Cancer
Pancreatic Ductal Adenocarcinoma

Interventions: Biological: Sacituzumab tirumotecan
Drug: Fluorouracil (5-FU)
Drug: Leucovorin (LV) or levoleucovorin
Drug: Rescue medication
Drug: Supportive care measures

First Posted Date: 2024-05-24

Last Posted Date: 2024-12-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 130

Registration Number: NCT06428409

Locations: 🇺🇸
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327), Mineola, New York, United States
🇦🇺
One Clinical Research ( Site 0002), Nedlands, Western Australia, Australia
🇺🇸
University of Florida College of Medicine ( Site 0281), Gainesville, Florida, United States

and more 38 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy